Who Might Consider NK Cell Therapy? Questions to Ask Before Consulting

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

If you or someone close to you is living with cancer, you may have come across NK cell therapy while searching for options that work alongside standard treatment. Before booking a consultation, it helps to know what questions to bring. This article explains who might consider NK cell therapy, what to ask about eligibility, and what to clarify about risks, costs and the legal framework in Japan. It is general information, not medical advice, and it cannot replace an assessment by a physician who knows your medical history.

The short answer: it depends on your situation and your doctor’s assessment

NK cell therapy is a cancer immune cell therapy in which your own natural killer (NK) cells are collected from a routine blood draw, activated and expanded at a specialized cell processing facility, and then returned to your body by intravenous infusion. It is not a replacement for surgery, chemotherapy or radiation therapy. At Grand Green Osaka Umekita Clinic in Osaka, it is described as an option that can be considered alongside standard cancer treatment, or after treatment with the aim of supporting immune function.

Whether it is suitable for you cannot be decided from a web page. Your type and stage of cancer, current treatments, blood test results, overall health and personal goals all matter. Anyone offering a firm answer without examining these factors deserves careful questioning. A responsible clinic will tell you plainly that the therapy has limits and that results vary from person to person.

What NK cells do, and why people look at this approach

NK cells are a type of lymphocyte that circulates in the blood. They are part of the innate immune system, which means they can recognize and attack abnormal cells, including cancer cells and virus-infected cells, without first receiving instructions from other immune cells. Researchers describe the process by which the immune system finds and removes abnormal cells as immune surveillance.

NK cell activity is known to decline with age, with chronic stress and as a result of cancer itself. The idea behind NK cell therapy is to return a larger number of more active NK cells to the body. Laboratory and early clinical studies on NK cells are indexed in PubMed, but the evidence for any individual cancer type is still evolving, and a single study should never be read as proof that a treatment will work for you. This is exactly why a careful discussion with a physician is important.

Questions about eligibility and how it fits with your current care

People who ask about NK cell therapy usually fall into a few groups: those who are receiving or have finished standard treatment and want to ask about immune support, those concerned about recurrence, and those who are interested in maintaining immune function. Each group has different needs, so it is useful to prepare specific questions for the first consultation.

• Is my cancer type and stage appropriate to discuss for this therapy, and what is the reasoning?
• How would the schedule fit around my surgery, chemotherapy or radiation therapy?
• Will the clinic coordinate with my current oncologist, and what records should I bring?
• What conditions or test results might make the therapy unsuitable for me?
• What are realistic goals, and how will progress be reviewed over time?

The therapy is generally described as unlikely to interfere with standard treatments, and the clinic can coordinate with the medical institution providing your standard care. Even so, you should keep your oncologist informed and never stop or delay recommended treatment because of an alternative option.

Understanding risks, side effects and the Japanese legal framework

Because the therapy uses your own cells, the risk of rejection is considered low, and serious side effects have rarely been reported. Temporary fever or fatigue may occur after infusion. That does not mean there is no risk. Blood collection and intravenous infusion carry the ordinary risks of any needle-based procedure, and individual reactions differ. Ask the physician to explain which side effects are possible, how they are managed and whom you should contact after you go home.

In Japan, cell therapies of this kind are provided under the Act on the Safety of Regenerative Medicine. Clinics submit a regenerative medicine provision plan to the authorities, and the cells are processed at a licensed facility. This framework is a form of oversight, but it does not guarantee a treatment outcome. NK cell therapy is also a self-pay treatment that is not covered by public health insurance in Japan, so you should confirm the full cost structure in advance.

Practical questions before you travel to Osaka

Many international patients and foreign residents ask about NK cell therapy. Grand Green Osaka Umekita Clinic is located in the Umeda area of Osaka and offers an information page for international patients, so you can begin by learning about the process in your own language. If you are considering medical travel, it is wise to ask about the following points before you decide.

• The number of visits required, and how many days you would need to stay in Japan
• Total fees, including consultation, tests, cell culture and each infusion, and what is not included
• Whether interpretation support is available during consultations and the informed consent process
• How follow-up will work after you return home, and how your home doctor can receive information
• What happens if you are not eligible after the initial consultation

Gather your recent diagnosis documents, imaging reports and treatment history before the consultation. Having these records ready allows the physician to give you a more meaningful answer.

Summary: prepare good questions and decide with your doctors

NK cell therapy is an immune cell approach that uses your own cells and may be discussed alongside standard cancer treatment. It is a self-pay option provided under Japan’s regenerative medicine framework, and its suitability, risks, schedule and fees must be confirmed through a consultation with a physician. It does not guarantee any result, and it should not take the place of the treatment your oncology team recommends.

If you would like to learn more, you can review the clinic’s NK cell therapy page, including the sections on features, flow, fees and frequently asked questions, and then consult the clinic in Osaka. Bring your questions, your records and your oncologist’s advice, and take the time you need to decide.

1. 1Prepare questionsEligibility, risks, fees
2. 2Gather recordsDiagnosis and treatment history
3. 3Consult a physicianSuitability is assessed
4. 4Keep your oncologist informed

This diagram is a conceptual summary of the article content

References

• PubMed: Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. (2020)
• PubMed: CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia. (2025)
• PubMed: NK cell-based cancer immunotherapy: from basic biology to clinical application. (2015)
• PubMed: Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8+ T cell activation in patients with advanced colorectal cancer. (2025)
• PubMed: The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. (2021)
• PMC: Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. (2010)
• PMC: Application of natural killer immunotherapy in blood cancers and solid tumors. (2023)
• PMC: Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors. (2023)
• MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.